LifeMap Sciences Announces Publication of Research Report Describing the
MalaCards Database of Human Diseases
ALAMEDA, Calif. -- April 18, 2013
LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX),
announced today that its MalaCards database has been recognized in a published
paper by the Weizmann Institute of Science research group under the
supervision of Prof. Doron Lancet from the Department of Molecular Genetics,
in collaboration with LifeMap Sciences. MalaCards (available as of Oct 2012
via www.malacards.org), is a database of human diseases and their annotations
that is modeled on the architecture and richness of the popular GeneCards^®
database of human genes (available at www.genecards.org). LifeMap Sciences
holds the exclusive worldwide license to market GeneCards^® and MalaCards,
from Yeda Research and Development Company Ltd., the commercial arm of the
Weizmann Institute of Science.
The publication titled “MalaCards: an integrated compendium for diseases and
their annotation” in the open access peer-reviewed journal DATABASE (Oxford
Press) can be viewed via the link
The publication describes the extensive disease classification, integration
and annotation utilized in MalaCards in order to establish a novel, inclusive,
database of human diseases, which portrays a web card or “MalaCard” for each
of close to 17,000 human diseases, with systematic search mechanisms.
MalaCards currently mines and merges 44 data sources, with additional sources
expected to be added in upcoming versions, and is empowered by the GeneCards^®
relational database, search engine, and GeneDecks set-analyses. Each MalaCard
is composed of 15 sections including: Summary, Related Diseases, Clinical
Features, Affiliated Genes, Drugs & Therapeutics, Genetic Tests, Anatomical
Context and References, as well as inter-disease connections. Upcoming
releases are expected to include hierarchical classification of diseases, and
disease set analyses, striving to make MalaCards an even more effective tool
for biomedical research.
LifeMap’s core integrated database suite, the discovery platform for
biomedical and stem cell research includes GeneCards^®, MalaCards and LifeMap
Discovery™, the database of embryonic development, stem cell research and
regenerative medicine. LifeMap clients and partners include dozens of large,
fee-paying pharmaceutical and biotechnology companies, as well as leading
government patent offices.
“The universe of human diseases has intrigued me for a long time as a complex
realm requiring the same systematic approach we have used in GeneCards^® for
human genes. It is a pleasure to see this vision come true,” said Professor
Doron Lancet, Ph.D., The Ralph D. and Lois R. Silver Professor of Human
Genomics, at the Weizmann Institute of Science.
“The publication describing MalaCards in a leading journal in its field is a
validation of the high scientific value and quality of this database of human
diseases,” stated Yaron Guan-Golan, Head of Marketing at LifeMap Sciences.
“Over our 10 year collaboration, the Lancet group at the Weizmann Institute of
Science has published more than 20 papers relating to GeneCards^®. We expect
to see many more publications demonstrating the leading edge scientific
quality of both MalaCards and GeneCards^®, and their ability to significantly
enhance basic research, as well as applied biomedical research.”
About LifeMap Sciences, Inc.
LifeMap Sciences’ (www.lifemapsc.com) core technology and business is based on
its integrated database suite, the discovery platform for biomedical and stem
cell research. This platform includes GeneCards^®, the leading human gene
database; LifeMap Discovery™, the database of embryonic development, stem cell
research and regenerative medicine; and MalaCards, the human disease database.
According to Google Analytics, the sites have generated more than 2,000,000
unique visitors with more than 13,000,000 page views in the past 12 months.
LifeMap Sciences also markets PanDaTox, an innovative, recently developed,
searchable database that can aid in the discovery of new antibiotics and
biotechnologically beneficial products.
In addition to database offerings, LifeMap Sciences is BioTime’s principal
marketing subsidiary for research products, including PureStem™ human
progenitor cell lines, GMP human embryonic stem (hES) cell lines, ESpan™
growth media for progenitor cell lines, and cell differentiation media for
non-therapeutic uses, via its LifeMap BioReagents™ portal. LifeMap Sciences
utilizes its databases as part of its online marketing strategy to reach life
sciences researchers at biotech and pharmaceutical companies and at academic
institutions and research hospitals worldwide.
In a therapeutic discovery collaboration with BioTime, LifeMap’s scientists
utilize LifeMap’s proprietary platform, including LifeMap Discovery™, its stem
cell database along with the GeneCards^® and MalaCards integrated database
suite, to aid in the development of BioTime’s proprietary PureStem™ human
progenitor cell lines into products for the treatment of human diseases,
especially degenerative diseases that might be treatable with cell replacement
therapies. The LifeMap Discovery™ platform will be used to select the
progenitor cell lines that are most likely to be useful in developing
cell-based regenerative medicine therapies for a wide range of diseases.
About BioTime, Inc.
BioTime, headquartered in Alameda, California, is a biotechnology company
focused on regenerative medicine and blood plasma volume expanders. Its broad
platform of stem cell technologies is enhanced through subsidiaries focused on
specific fields of application. BioTime develops and markets research products
in the fields of stem cells and regenerative medicine, including a wide array
of proprietary PureStem™ cell lines, HyStem^® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (formerly known as
HyStem^®-Rx), a biocompatible, implantable hyaluronan and collagen-based
matrix for cell delivery in human clinical applications. BioTime's therapeutic
product development strategy is pursued through subsidiaries that focus on
specific organ systems and related diseases for which there is a high unmet
medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd.
is developing therapeutic products derived from stem cells for the treatment
of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte
Corporation is developing therapeutic applications of stem cells to treat
orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation,
focuses on the diagnostic and therapeutic applications of stem cell technology
in cancer, including the diagnostic product PanC-Dx™ currently being developed
for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is
developing applications of BioTime's proprietary induced pluripotent stem cell
technology to reverse the developmental aging of human cells to treat
cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences,
Inc. markets GeneCards^®, the leading human gene database, as part of an
integrated database suite that also includes the LifeMap Discovery™ database
of embryonic development, stem cell research and regenerative medicine, and
MalaCards, the human disease database. LifeMap Sciences also markets BioTime
research products and PanDaTox, an innovative, recently developed, searchable
database that can aid in the discovery of new antibiotics and
biotechnologically beneficial products. Asterias Biotherapeutics, Inc. is a
new subsidiary being used to acquire the stem cell assets of Geron
Corporation, including patents and other intellectual property, biological
materials, reagents and equipment for the development of new therapeutic
products for regenerative medicine. BioTime's lead product, Hextend^®, is a
blood plasma volume expander manufactured and distributed in the U.S. by
Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive
licensing agreements. Additional information about BioTime can be found on the
web at www.biotimeinc.com.
About the Weizmann Institute of Science and GeneCards
The Weizmann Institute of Science in Rehovot, Israel, is one of the world's
top-ranking multidisciplinary research institutions. Noted for its
wide-ranging exploration of the natural and exact sciences, the Institute is
home to 2,700 scientists, postdoctoral fellows, Ph.D. and M.Sc. students, and
scientific, technical and administrative staff. In addition, visiting
scientists and their families – over 500 from 35 countries in 2010 are
regularly hosted at the Institute. The Institute was founded in 1934 following
a donation to Dr. Chaim Weizmann, a noted biochemist and biotechnologist, who
envisioned the establishment of a world-class scientific research center in
Israel, and later also became the first President of the State of Israel.
Weizmann Institute’s Feinberg Graduate School was established in 1958, where
about 1000 M.Sc. and Ph.D. students are enrolled in studies covering the
Institute’s 18 departments, which are grouped into five faculties:
Biochemistry, Biology, Chemistry, Physics, and Mathematics and Computer
Science. The Institute’s technology transfer arm, Yeda Research and
Development Co. was the first company of its kind in Israel, and is currently
one of the most successful worldwide. Institute research efforts include the
search for new ways of fighting disease and hunger, examining leading
questions in mathematics and computer science, probing the physics of matter
and the universe, creating novel materials and developing new strategies for
protecting the environment. Particular excellence in bioinformatics and
systems biology is manifested, among others, in the GeneCards project,
initiated in 1996, under the leadership of Prof. Doron Lancet of the Dept. of
Molecular Genetics, Head of the Crown Human Genome Center. A team of 10 led by
Marilyn Safran continuously innovates and keeps GeneCards as a world-top human
gene compendium, automatically mining and integrating 100 worldwide web
Statements pertaining to future financial and/or operating results, future
growth in research, technology, clinical development, and potential
opportunities for BioTime and its subsidiaries, along with other statements
about the future expectations, beliefs, goals, plans, or prospects expressed
by management constitute forward-looking statements. Any statements that are
not historical fact (including, but not limited to statements that contain
words such as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or commercialization of
potential products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking statements
and as such should be evaluated together with the many uncertainties that
affect the business of BioTime and its subsidiaries, particularly those
mentioned in the cautionary statements found in BioTime's Securities and
Exchange Commission filings. BioTime disclaims any intent or obligation to
update these forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list:
Peter Garcia,510-521-3390, ext 367
Chief Financial Officer
Judith Segall, 510-521-3390, ext 301
LifeMap Sciences, Inc.
Press spacebar to pause and continue. Press esc to stop.